Japan’s largest drug wholesaler 
The distributor, which also sells cosmetics and sundries, is seeking to boost profit, excluding extraordinary items, to ¥100 billion ($694 million) by March 2027 from ¥65 billion in the latest fiscal year. “To do so, we need growth outside of organic means, including M&A,” 
Medipal is expanding into areas such as animal health products and drug development as margins ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.


